Monte Rosa Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Monte Rosa Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains
The development tests whether Monte Rosa Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects
The story matters when it changes Monte Rosa Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Investors are testing whether Monte Rosa Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Cours Monte Rosa Therapeutics, Inc.
The story matters when it changes Monte Rosa Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest GLUE filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Monte Rosa Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →